{
    "name": "reslizumab",
    "comment": "Rx",
    "other_names": [
        "Cinqair"
    ],
    "classes": [
        "Interleukin Inhibitors",
        "Monoclonal Antibodies",
        "Anti-asthmatics"
    ],
    "source": "https://reference.medscape.com/drug/cinqair-reslizumab-1000068",
    "pregnancy": {
        "common": [
            "Data are insufficient regarding drug-associated risk during pregnancy",
            "Monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters of pregnancy",
            "Reslizumab has a long half-life; this should be taken into consideration"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Increased risk of preeclampsia in women with poorly or moderately controlled asthma",
                    "Prematurity, low birth weight, and small for gestational age observed in neonates whose mothers have poor or moderate asthma control",
                    "Asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control"
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "Not teratogenic in mice or rabbits; data based on 2 single-dose studies in pregnant mice and rabbits during organogenesis 0.4, 1.5, and 6 times the exposures achieved at the maximum recommended human dose (MRHD) in mice on an AUC basis and 0.67, 3.3, and 17 times the exposures achieved at the MRHD in rabbits on a mg/kg basis"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk; however, human IgG is known to be present in human milk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Anaphylaxis occurred in 0.3% of patients in placebo-controlled studies",
                "Manifestations included dyspnea, decreased oxygen saturation, wheezing, vomiting, and skin and mucosal involvement, including urticaria",
                "Observe patients for an appropriate period after infusion; healthcare professionals should be prepared to manage anaphylaxis that can be life-threatening",
                "Discontinue immediately if the patient experiences anaphylaxis"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity to reslizumab or its excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylaxis reported observed during or within 20 minutes after completion of the IV infusion and reported as early as the second dose (see Black Box Warnings)",
                "Not for use to treat acute asthma symptoms or acute exacerbations",
                "No clinical studies have been conducted to assess reduction of maintenance corticosteroid dosages following administration of reslizumab; do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of reslizumab therapy",
                "Diverse malignancies observed with reslizumab vs placebo in clinical trials (0.6% vs 0.3%)",
                "Treat patients with pre-existing helminth infections before initiating reslizumab; if patients become infected during reslizumab treatment and do not respond to antihelminth treatment, discontinue reslizumab until infection resolves"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Elevated CPK",
            "percent": "20"
        },
        {
            "name": "transient",
            "percent": "5.4"
        },
        {
            "name": "Treatment",
            "percent": "2.6"
        },
        {
            "name": "emergent antibody response",
            "percent": "2.2"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "1"
        },
        {
            "name": "Musculoskeletal",
            "percent": "10"
        },
        {
            "name": "Myalgias",
            "percent": "0.8"
        },
        {
            "name": "Elevated CPK",
            "percent": "0.6"
        },
        {
            "name": "x ULN",
            "percent": "0.3"
        },
        {
            "name": "Malignancy",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        }
    ]
}